
Dyne Therapeutics (DYN) Stock Forecast & Price Target
Dyne Therapeutics (DYN) Analyst Ratings
Bulls say
Dyne Therapeutics Inc. has shown promising clinical results for its pipeline candidates, particularly with DYNE-251, which achieved approximately a 7% increase in normal dystrophin levels and demonstrated favorable safety alongside multiple functional improvements in Phase I trials. DYNE-101 has also displayed meaningful enhancements in disease pharmacology, evidenced by significant advances in biomarkers and patient-reported outcomes related to CNS symptoms, as well as sustained functional gains in various tests, suggesting its progress towards potential accelerated approval. Overall, the combination of compelling efficacy data and acceptable safety profiles for both DYNE-251 and DYNE-101 positions Dyne Therapeutics favorably for future clinical advancements and potential market success.
Bears say
Dyne Therapeutics Inc faces a negative outlook due to concerns regarding the efficacy and safety profile of its clinical candidates, particularly as the 6-month data for the CASI-22 cohort indicated a significant drop in splicing improvement from 25% at 3 months to 3% at 6 months. Additionally, potential payer headwinds related to reimbursement for DYNE-251 following competitive treatments may further depress the company's stock price. The inherent clinical development and regulatory risks, particularly if unexpected safety findings arise, could substantially hinder the commercial uptake of Dyne's therapeutics, adversely impacting financial performance.
This aggregate rating is based on analysts' research of Dyne Therapeutics and is not a guaranteed prediction by Public.com or investment advice.
Dyne Therapeutics (DYN) Analyst Forecast & Price Prediction
Start investing in Dyne Therapeutics (DYN)
Order type
Buy in
Order amount
Est. shares
0 shares